Intralymphatic allergen-specific immunotherapy

Author: Sung-Yoon KANG ^{1
,

2} ; Joo Hyun JUNG ; Sang Min LEE ; Sang Pyo LEE
Author Information

1. Division of Pulmonology and Allergy, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon
2. 2Department of Otolaryngology-Head and Neck Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
Publication Type:REVIEW
From:Allergy, Asthma & Respiratory Disease 2020;8(2):53-65
CountryRepublic of Korea
Language:Korean
Abstract: Although allergen-specific immunotherapy (AIT) is a standard treatment for allergic diseases, only 5% or less of patients in whom AIT is indicated have been receiving immunotherapy because AIT needs a long-term therapeutic duration of up to 5 years. To overcome this limitation of conventional AIT, Kündig and his colleagues first introduced intralymphatic immunotherapy (ILIT) in patients with allergic rhinitis, publishing their results in 2008. Since then, 10 clinical trials that evaluated therapeutic efficacies and adverse effects of ILIT have been conducted. This article reviews the clinical trials of ILIT and suggests unmet needs in research fields of ILIT.